The trial stands as a robust case study for methodological comparison, given its expansive scope examining oncogenic RET alterations across a diverse range of solid tumors, like Non-Small Cell Lung Cancer (NSCLC) and Medullary Thyroid Cancer (MTC), and other solid tumors. This evidence concerns the gene RET and medullary thyroid gland carcinoma.